Generic Medicine Info
Indications and Dosage
Acute pain, Postoperative pain
Adult: Usual dose: 20 mg, repeated 6 hourly if needed. Max: 120 mg daily. Patient must lie down during and for 15-20 minutes after administration.

Acute pain, Postoperative pain
Adult: Usual dose: 20 mg via slow IV bolus infusion over at least 15 minutes, repeated 4 hourly if needed. Max: 120 mg daily. Patient must lie down during and for 15-20 minutes after administration.

Moderate acute pain, Moderate chronic pain
Adult: For the relief of pain including postoperative, dental, musculoskeletal, acute traumatic and cancer pain: Initially, 60 mg tid. Usual dose: 30-90 mg tid, adjusted according to patient response.
Child: ≥12 years Same as adult dose.
Elderly: Initially, 30 mg tid.
Renal Impairment
ESRD: Dose reduction may be necessary.
May be taken with or without food. May be taken w/ meals if GI discomfort occurs.
IV infusion: May be diluted in 0.9% NaCl solution or 5% dextrose in water.
History of convulsive disorders. IM/IV: Urinary retention linked to urinary or prostate disorders, angle-closure glaucoma. Oral: Concomitant use with MAOIs.
Special Precautions
Patient with angle-closure glaucoma, urinary retention, benign prostatic hyperplasia, CV disease or history of ischaemic heart disease. Patient concomitantly taking TCA. Not recommended for the treatment of MI. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. IM/IV: Not indicated for the treatment of chronic pain; not advisable for use in the elderly.
Adverse Reactions
Significant: Anticholinergic effects (e.g. blurred vision, xerostomia, constipation, urinary retention), sympathomimetic effects (e.g. tachycardia, exacerbation of angina); drug dependence and abuse. Rarely, transient pink discolouration of urine.
Cardiac disorders: Palpitations.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain.
Immune system disorders: Angioedema, allergic reactions.
Nervous system disorders: Dizziness, drowsiness, headache, paraesthesia, tremor, convulsion, lightheadedness.
Psychiatric disorders: Insomnia, nervousness, confusion, hallucination.
Skin and subcutaneous tissue disorders: Diaphoresis.
Vascular disorders: Hypotension, syncope.
Patient Counseling Information
This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor renal and hepatic function; signs of anticholinergic effects (e.g. nausea, sweating) particularly within approx 15 minutes of administration (IM/IV).
Symptoms: Tachycardia with hyperdynamic circulation; agitation, hallucinations, convulsions, and coma. Management: Supportive and symptomatic treatment. Perform gastric lavage, or induce vomiting or diuresis. May administer activated charcoal to prevent absorption. May give diazepam for convulsions and hallucinations, and β-adrenergic blockers for CV complications.
Drug Interactions
May cause serotonin toxicity (including serotonin syndrome) with TCAs and SSRIs. May result in additive adverse effects with other anticholinergic or sympathomimetic agents.
Potentially Fatal: May increase the risk of serotonin toxicity (including serotonin syndrome) with MAOIs.
Food Interaction
Alcohol may increase the CNS depressant effects of nefopam.
Lab Interference
May cause false-positive result with urinary screening test for opioids and benzodiazepines.
Description: Nefopam is a potent, centrally-acting, non-opioid analgesic with anticholinergic and sympathomimetic actions. Its exact mechanism is unclear; however, in vitro studies suggest that it inhibits the reuptake of norepinephrine, serotonin and dopamine.
Onset: Rapid.
Absorption: Absorbed from the gastrointestinal tract. Bioavailability: 40% (oral). Time to peak plasma concentration: Approx 1-3 hours (oral); 0.5-1 hour (IM).
Distribution: Enters breast milk. Plasma protein binding: Approx 73%.
Metabolism: Extensively metabolised in the liver to form desmethylnefopam, nefopam N-oxide, and N-glucuronide.
Excretion: Mainly via urine (87%, <5% as unchanged drug); faeces (approx 8%). Elimination half-life: Approx 4 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Nefopam, CID=4450, (accessed on Jan. 22, 2020)

Tab: Store below 25°C. Solution for inj: Store below 30°C.
MIMS Class
Analgesics (Non-Opioid) & Antipyretics
ATC Classification
N02BG06 - nefopam ; Belongs to the class of other analgesics and antipyretics.
Acupan 20 mg/2 mL, Solution for Injection (DKSH Malaysia Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 03/05/2021.

Anon. Nefopam. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/05/2021.

Buckingham R (ed). Nefopam Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 03/05/2021.

iNova Pharmaceuticals (New Zealand) Limited. Acupan 30 mg Tablets data sheet 10 July 2018. Medsafe. Accessed 03/05/2021.

Joint Formulary Committee. Nefopam Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 03/05/2021.

Nefopam Hydrochloride 30 mg Film-Coated Tablets (Key Pharmaceuticals Ltd.). MHRA. Accessed 03/05/2021.

Disclaimer: This information is independently developed by MIMS based on Nefopam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in